ReWalk Robotics (NASDAQ:RWLK) Downgraded by Zacks Investment Research

ReWalk Robotics (NASDAQ:RWLK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. “

Get ReWalk Robotics alerts:

NASDAQ:RWLK opened at $1.83 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.23 and a quick ratio of 1.84. ReWalk Robotics has a one year low of $0.41 and a one year high of $2.55. The company has a market cap of $45.31 million, a PE ratio of -1.19 and a beta of 3.42. The firm has a 50-day moving average of $1.43 and a 200-day moving average of $1.28.

ReWalk Robotics (NASDAQ:RWLK) last released its quarterly earnings results on Tuesday, November 10th. The medical device company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $1.09 million. ReWalk Robotics had a negative net margin of 282.04% and a negative return on equity of 109.54%. On average, equities research analysts expect that ReWalk Robotics will post -0.82 earnings per share for the current fiscal year.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.

See Also: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on ReWalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.